Answers are grounded in this paper and cite their sources.
Pt(IV) prodrugs are highly promising platform for anticancer agents due to the ability to fine-tune the structure and properties of the prodrug by varying the axial ligand conjugated with the Pt(IV) core. In this study, we have synthesized photoactivated Pt(IV) prodrugs with NIR-absorbing cyanine and chalcone in axial positions, which combine the advantages of dual-target chemotherapy, controlled photoactivation, photodynamic therapy, and fluorescent NIR bioimaging. The cyanine-chalcone-based prodrug Pt-4 demonstrated the ability to generate ROS, release carboplatin intracellularly and promote p53 expression under 660 nm light. Pt-4 prodrug demonstrated superior pharmacokinetic properties to carboplatin and excellent fluorescent imaging of CT-26 tumors. In vivo, Pt-4 prodrug + 660 nm light stimulated adaptive immune response in LLC tumors and significantly inhibited tumor growth of homograft CT-26 tumor. Our findings demonstrate excellent potential of Pt(IV)-carbocyanine light-activatable platform for tumor imaging, drug delivery and tumor eradication.
No takes yet. Share an insight, caveat, or question.
Spector et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: